Corcept Therapeutics Inc (NAS:CORT)
$ 27.04 0.44 (1.65%) Market Cap: 2.82 Bil Enterprise Value: 2.40 Bil PE Ratio: 25.51 PB Ratio: 5.13 GF Score: 90/100

Q1 2021 Corcept Therapeutics Inc Earnings Call Transcript

May 06, 2021 / 09:00PM GMT
Release Date Price: $21.71 (+0.23%)
Operator

Good day, and welcome to the Corcept Therapeutics Conference Call. Today's conference is being recorded. (Operator Instructions)

At this time, I'd like to turn the conference over to Atabak Mokari. Please go ahead.

Atabak Mokari
Corcept Therapeutics Incorporated - CFO

Good afternoon. I'm Atabak Mokari, Corcept's Chief Financial Officer. Today, we issued 3 press releases: one, announcing the positive outcome of our 178-patient Phase II trial of relacorilant in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer.

Second, announcing markedly decreased liver fat in patients in our Phase II trial of miricorilant as a potential treatment for nonalcoholic steatohepatitis of NASH; and the third, providing a clinical update and announcing our financial results for the first quarter. Copies of all of these are available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC.

Today's call is being recorded. A replay will be available on the Investors Past

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot